Affiliation:
1. Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational Research (CENTRE), University
College of Engineering, Anna University BIT Campus, Tiruchirappalli, Tamil Nadu, India
Abstract
Abstract:
The importance of siRNA in nano drug delivery systems to target important pulmonary disorders,
such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and others, is reviewed in this
perspective. The great majority of lung illnesses are caused by protein misfolding. As a result, siRNA-based
therapies are increasingly being used to target the gene. Given the difficulties of delivering bare siRNA, siRNA
protection may ensure its efficacy in gene therapy. These issues could be solved with a nano-based siRNA
delivery systems. In this context, a siRNA-based nanocarrier for major pulmonary disorders has been explored.
Funder
Department of Health Research, New Delhi
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Reference24 articles.
1. Gandomani S.H.; Asgari-Tarazoj A.; Ghoncheh M.; Yousefi S.M.; Delaram M.; Salehiniya H.; Lung cancer in the world: The incidence, mortality rate and risk factors. WCRJ 2017,4(3),e911
2. Mao Y.; Yang D.; He J.; Krasna M.J.; Epidemiology of lung cancer. Surg Oncol Clin N Am 2016,25(3),439-445
3. Herbst R.S.; Heymach J.V.; Lippman S.M.; Lung cancer. N Engl J Med 2008,359(13),1367-1380
4. Hirsch F.R.; Scagliotti G.V.; Mulshine J.L.; Lung cancer: Current therapies and new targeted treatments. Lancet 2017,389(10066),299-311
5. Soria J.C.; Marabelle A.; Brahmer J.R.; Gettinger S.; Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 2015,21(10),2256-2262